An experimental therapy that uses the body's own immune system cells may beat a standard treatment for patients with advanced melanoma, a new clinical trial finds.
While melanoma remains the most deadly type of skin cancer, new research has found that a subset of patients with early disease are at very low risk of dying.
For the millions of people who live with vitiligo, a disease that robs the skin of its natural color, a newly approved cream called ruxolitinib (Opzelura) is quickly becoming a game changer.
